Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David E. Avigan, M.D.

Co-Author

This page shows the publications co-authored by David Avigan and Daniel DeAngelo.
Connection Strength

0.538
  1. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
    View in: PubMed
    Score: 0.196
  2. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
    View in: PubMed
    Score: 0.183
  3. Leukemia derived dendritic cells (LDCs) may be ineffective as a cancer vaccine for acute myeloid leukemia (AML). J Clin Oncol. 2005 Jun; 23(16_suppl):2527.
    View in: PubMed
    Score: 0.082
  4. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
    View in: PubMed
    Score: 0.056
  5. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res. 2004 Dec; 28(12):1303-12.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.